Gilead’s New Hepatitis C Drug Approved by FDA, Priced at $74,760
- Epclusa is first treatment for all forms of the disease
- Drug will mainly be used in patients with genotypes 2 and 3
Gilead's Hepatitis C Drug Approved by FDA
This article is for subscribers only.
Gilead Sciences Inc.’s hepatitis C drug was approved by U.S. regulators for all forms of the viral disease, making it the first treatment with such a comprehensive label.
The drug, called Epclusa, can be used by patients with any of the six genotypes of hepatitis C, the U.S. Food and Drug Administration said Tuesday in a statement. The liver disease affects 130 million to 150 million people globally, according to the World Health Organization.